J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.
( MENAFN - GlobeNewsWire - Nasdaq) Dublin, Jan. 30, 2025 (GLOBE NEWSWIRE) -- The "Pharmaceutical Regulatory Affairs in Asia Training Course" has been added to ResearchAndMarkets.com's offering.